Patents Issued in February 1, 2022
  • Heterocyclic compound
    Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11236100
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Cyanoaryl substituted benz(othi)oxanthene compounds
    Patent number: 11236101
    Abstract: The present invention relates to a cyanoaryl substituted compound of formula (I), (I) wherein m is 0-4; R2, R3, R4 and R5 are selected from hydrogen, chlorine, bromine and C6-C24-aryl, which carries one to three cyano; each R1 independently from each other is selected from bromine, chlorine, cyano, —NRaRb, C1-C24-alkyl, C1-C24-haloalkyl, C1-C24-alkoxy, C1-C24-haloalkoxy, C3-C24-cycloalkyl, heterocycloalkyl, heteroaryl, C6-C24-aryl, C6-C24-aryloxy, C6-C24-aryl-C1-C10-alkylene, etc., with the proviso that at least one of the radicals R1, R2, R3, R4 and R5 is C6-C24-aryl, which carries one to three cyano; X is O, S, SO or SO2; A is a diradical of the formulae (A.1), (A.2), (A.3), or (A.4) wherein *, R6, (R7)n, (R8)o and (R9)p are as defined in the claims and in the description.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: February 1, 2022
    Assignee: BASF SE
    Inventors: Martin Koenemann, Gerhard Wagenblast, Sorin Ivanovici, Hannah Stephanie Mangold, Hisatoshi Kura, Mamiko Matsunaga
  • Oxabicycloheptane prodrugs
    Patent number: 11236102
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: February 1, 2022
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Bifunctional compounds
    Patent number: 11236103
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 11236104
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: February 1, 2022
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Bicyclic compounds and methods of use
    Patent number: 11236105
    Abstract: The present invention provides compounds that modulate protein function, specifically phosphodiesterase 4 (PDE4). The invention provides methods of treating, ameliorating, and/or preventing diseases, disorders, and conditions associated with PDE4. Compositions, including in combination with other inflammatory mediators, are also provided.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Robert Sullivan, Paul E. Erdman, Eduardo Torres, Leah Fung, Kyle W. H. Chan, Frank Mercurio
  • Cycloalkane-1,3-diamine derivative
    Patent number: 11236106
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: February 1, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • Crystal of tricyclic compound
    Patent number: 11236107
    Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: February 1, 2022
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Shilan Liu, Dahai Wang, Guibai Liang, Honglin Wang, Guoping Hu, Jian Li, Shuhui Chen
  • Functionalized heterocycles as antiviral agents
    Patent number: 11236108
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: February 1, 2022
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Joseph D. Panarese, Nathaniel Thomas Kenton, Samuel Bartlett, Dexter Davis, Yat Sun Or
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 11236109
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: February 1, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
    Patent number: 11236110
    Abstract: The present invention relates to (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one salts, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor and/or ?-opioid receptor associated disease.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 1, 2022
    Assignee: ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Carmen Almansa-Rosales, Nicolas Tesson
  • Hepatitis B antiviral agents
    Patent number: 11236111
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Xiaowen Peng, Wei Li, Jorden Kass, Hui Cao, Byung-Chul Suh, Jiajun Zhang, Yat Sun Or
  • Crystal form and salt form of TGF-?RI inhibitor and preparation method therefor
    Patent number: 11236112
    Abstract: Disclosed in the present invention are a crystal form and salt form of a TGF-?R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: February 1, 2022
    Assignee: GENFLEET THERAPEUTICS (SHANGHAI) INC.
    Inventors: Lifang Wu, Huijun He, Jianyu Lu, Charles Z. Ding, Lihong Hu, Weidong Li, Shenyi Shi, Jian Li, Shuhui Chen
  • Hydrocarbon-soluble halogen and thiolate/magnesium exchange reagents
    Patent number: 11236113
    Abstract: The invention relates to hydrocarbon-soluble halogen or thiolate/magnesium exchange reagents of the general formula R1MgR11-n(OR3)n.LiOR2.(1?n)LiOR3.aDonor in which: R1 is a C1-C8 alkyl and OR2 as well as OR3 are same or different and represent primary, secondary, or tertiary alkoxide residues having 3 to 18 carbon atoms, wherein R2 and/or R3 can for their part contain an alkoxy substituent OR4; a assumes a value of 0 to 2, n assumes a value between 0 and 1, and the donor is an organic molecule containing at least 2 nitrogen atoms.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: February 1, 2022
    Assignee: Albemarle Germany GmbH
    Inventors: Paul Knochel, Dorothée Ziegler, Meike Simon
  • Heterocyclic compound, light-emitting element, light-emitting device, electronic device, and lighting device
    Patent number: 11236114
    Abstract: Provided are a heterocyclic compound which emits blue light and is represented by General Formula (G1) below, and a light-emitting element, a light-emitting device, an electronic device and a lighting device which are formed using the heterocyclic compound represented by General Formula (G1) below. The use of the heterocyclic compound represented by General Formula (G1) makes it possible to provide a light-emitting element which has high emission efficiency, and also a light-emitting device, an electronic device and a lighting device which have reduced power consumption.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: February 1, 2022
    Inventors: Hiroki Suzuki, Tsunenori Suzuki, Satoshi Seo
  • Solid forms of substituted benzoxaborole and compositions thereof
    Patent number: 11236115
    Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: February 1, 2022
    Assignee: 5Metis, Inc.
    Inventors: Chun Yu Liu, Marissa Caroline Aubrey, Yong-Kang Zhang, Michael Samuels
  • Silicon compound
    Patent number: 11236116
    Abstract: The present disclosure relates to a silicon compound represented by Formula 1 below: wherein R1 to R6 are each independently selected from a hydrogen, a hydrocarbyl group and a non-hydrocarbyl group, L is a direct bond or hydrocarbylene, X is oxygen (O) or sulfur (S), Y and Z are each independently selected from NR7, O, and S, where R7 is a hydrogen, a hydrocarbyl group, or a non-hydrocarbyl group, and Y and Z are not simultaneously NR7, and A is an n-valent radical, where n is an integer of 1 to 6.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: February 1, 2022
    Assignees: SK Innovation Co., Ltd., SK-Materials Co., Ltd.
    Inventors: Cheol Woo Kim, Min Kyung Seon, Yu Na Shim, Jae Hoon Kwak, Young Bom Kim, Jong Ho Lee, Jin Kyung Jo
  • Alkoxysilane compound or salt thereof, preparation method therefor, and hair composition containing same
    Patent number: 11236117
    Abstract: The present invention relates to an alkoxysilane salt compound having a novel structure, a preparation method therefor, and a hair composition containing the same. The alkoxysilane salt compound increases the storage stability and the dispersion stability of a hair composition in accordance with the formation of a self-assembly in the aqueous phase and can provide a continuous conditioning effect for hair.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 1, 2022
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Jae Won Yoo, Yoon Kyun Hwang, Sung-Ah Bin, Yong Jin Kim, John Hwan Lee
  • Selective cyclocarbonylative coupling of 2-iodophenols with terminal alkynes catalyzed by bridged bis(NHC)Pd(II)Brcatalysts
    Patent number: 11236118
    Abstract: Palladium catalysts, methods of synthesizing palladium-carbene catalysts, and methods of producing chromones and aurones using palladium-N-heterocyclic carbene (NHC) catalysts are provided. In some implementations, the palladium catalysts include a bridged palladium catalyst with distorted square planar geometry around the center palladium atom. The catalysts can be used in cyclocarbonylative Sonogashira cross-coupling reactions to produce chromones and aurones at a high yield. The selectivity of the catalysts can be adjusted by adjusting reaction conditions.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: February 1, 2022
    Assignee: King Fahd University of Petroleum & Minerals
    Inventors: Bassam El Ali, Waseem Mansour, Mohammed Fettouhi
  • Chemically stable lignin derivative and method for preparing same
    Patent number: 11236119
    Abstract: A lignin derivative including a unit of general formula (I): in which R1, R2, R3 and R4, which may be identical or different, each represent a hydrogen atom, a methoxy group —OMe, a hydroxyl group, where appropriate protected by a protective group of a hydroxyl function, or a unit R5 represents a hydrogen atom, a protective group of a hydroxyl function or a unit; A represents an oxygen atom, a sulfur atom, an —NH group or an —NR? group; and R?1, R?2, R?3 and R?4 each represent a hydrogen atom or a substituent not including a mesomeric-effect electron-withdrawing group conjugated to the aromatic ring, a substituent from R?1, R?2, R?3 and R?4 representing the covalent bond with the benzylic carbon.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: February 1, 2022
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET ENVIRONNEMENT, INSTITUT NATIONAL D'ENSEIGNEMENT SUPERIEUR POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Laurent Roumeas, Guillaume Billerach, Eric Dubreucq, Hélène Fulcrand
  • Azithromycin derivatives with epithelial barrier enhancement properties
    Patent number: 11236120
    Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: February 1, 2022
    Assignee: EPIENDO PHARMACEUTICALS EHF
    Inventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
  • Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
    Patent number: 11236121
    Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: February 1, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Triterpene amine derivatives
    Patent number: 11236122
    Abstract: The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 1, 2022
    Assignees: DFH THERAPEUTICS, The United States Of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Theodore J. Nitz, Carl T. Wild, David E. Martin, Eric O. Freed
  • Method for preparation of peptides with psWang linker
    Patent number: 11236123
    Abstract: The invention discloses a method for the preparation of a peptide by liquid phase coupling of two fragments, an N-terminal fragment and a C-terminal fragment of the desired peptide, wherein the C-terminal fragment is protected on its C-terminal COOH by a psWang linker; the method is demonstrated with liraglutide wherein the C-terminal fragment carries the Palmitoyl-Glu-OtBu residue on the Lys.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: February 1, 2022
    Assignee: Polypeptide Laboratories Holding (PPL) AB
    Inventors: Luciano Forni, Daniel Carbajo Lopez, Fernando Albericio Palomera
  • Method and composition for hydrolyzing eggshell membrane
    Patent number: 11236124
    Abstract: The present invention relates to a method for hydrolyzing eggshell membrane, comprising the step of treating a suitable amount of eggshell in a solution containing a denaturing agent, a reducing agent, a buffer, and an enzyme. The invention also relates to a composition for hydrolyzing eggshell membrane according to the preceding method.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: February 1, 2022
    Assignee: EGGNOVO S.L.
    Inventors: Manuel A. La Nuez García, Andrés Aguirre González
  • Mixed bed ion exchange adsorber
    Patent number: 11236125
    Abstract: The present invention refers to new species of an ion exchange adsorber which is suitable for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies. The invention especially refers to a process for purifying biological samples by separating biomolecules of interest and impurities, comprising steps of contacting a sample with said chromatography media consisting of fibers, said fibers having imparted thereon functionality enabling ion exchange chromatography and/or hydrophobic interaction.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: February 1, 2022
    Assignee: EMD Millipore Corporation
    Inventors: Matthew T. Stone, John P. Amara
  • Methods for enhanced removal of impurities during protein A chromatography
    Patent number: 11236126
    Abstract: Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 1, 2022
    Assignee: GENZYME CORPORATION
    Inventor: Carl A. Beigie
  • Modulation of antigen immunogenicity by addition of epitopes recognized by NKT cells
    Patent number: 11236127
    Abstract: The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: February 1, 2022
    Assignee: Imnate Sarl
    Inventor: Jean-Marie Saint-Remy
  • Method of preparing stapled peptides
    Patent number: 11236128
    Abstract: Described herein is an operationally simple, one-pot solid-supported preparation of saturated stapled peptides. Following completion of ruthenium-catalysed metathesis, solid-phase transfer hydrogenation was achieved using triethylhydrosilane at elevated temperatures. The utility of the method has been demonstrated on 14- and 16-mer peptides to yield the corresponding cyclic a-helix stabilised stapled peptides.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: February 1, 2022
    Assignee: Agency for Science, Technology and Research
    Inventors: Tsz Ying Yuen, Charles William Johannes, Gerard Hilinski
  • IL-17A binding peptides and medical uses thereof
    Patent number: 11236129
    Abstract: The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: February 1, 2022
    Assignee: Dompe' Farmaceutici S.P.A.
    Inventors: Marcello Allegretti, Andrea Aramini, Andrea Beccari, Marica Gemei, Flavio Mantelli
  • Divalent nucleobase compounds and uses therefor
    Patent number: 11236130
    Abstract: Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: February 1, 2022
    Assignee: Carnegie Mellon University
    Inventors: Danith H. Ly, Suresh Kumar Gopalsamy, Arunava Manna
  • Re-directed immunotherapy
    Patent number: 11236131
    Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: February 1, 2022
    Assignee: The University of Birmingham
    Inventors: Mark Cobbold, David Millar
  • Nepovirus coat protein fusion polypeptides and their use
    Patent number: 11236132
    Abstract: The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: February 1, 2022
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Lorène Belval, Gérard Demangeat, Caroline Hemmer, Christophe Ritzenthaler
  • Chimeric receptor binding proteins for use in bacterial delivery vehicles
    Patent number: 11236133
    Abstract: The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 1, 2022
    Assignee: Eligo Bioscience
    Inventor: Jesus Fernandez Rodriguez
  • Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
    Patent number: 11236134
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 1, 2022
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • and immunogenic composition containing the same as well as its use
    Patent number: 11236135
    Abstract: In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: February 1, 2022
    Assignee: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
    Inventors: Marc Erhardt, Sebastian Felgner, Dino Kocijancic, Siegfried Weiss
  • Methods of producing glycosylated proteins
    Patent number: 11236136
    Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 1, 2022
    Assignees: LIMMATECH BIOLOGICS AG, EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH
    Inventors: Michael L. Wetter, Michael T. Kowarik, Amirreza Faridmoayer, Manuela Mally, Christian A. Lizak, Markus Aebi, Chia-wei Lin, Ivan Hang, Timothy Keys
  • Recombinant type 2 allergen protein and its preparation method and application
    Patent number: 11236137
    Abstract: Provided are an optimized Der f2 gene, a recombinant Der f2 protein encoded thereby, a vector comprising said gene, and a Pichia pastoris strain. Also provided are an expression method, a purification method, and an application of the recombinant Der f2 protein.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 1, 2022
    Assignee: ZonHon Biopharma Institute, Inc.
    Inventors: Bruce Yong Ma, Yu Fan, Jun Wang, Anliang Wang
  • Peptide, method and composition for melanin polymerization and hair darkening
    Patent number: 11236138
    Abstract: An isolated peptide comprises a motif of RRWQW (SEQ ID NO: 1) for melanin polymerization and hair darkening is provided. Also disclosed herein are methods and compositions for hair darkening in a mammal subject.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 1, 2022
    Assignee: RENORIGIN INNOVATION INSTITUTE CO., LTD.
    Inventors: Hsiu-Chin Huang, Hsuan Lin
  • Combination immunotherapy
    Patent number: 11236139
    Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors. Exemplary checkpoint molecules include CTLA-4, a CTLA-4 receptor, PD-1, PD1-L1, PD1-L2, 4-1BB, OX40, LAG-3, TIM-3 or a combination thereof. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 1, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Steven M. Dubinett, Sherven Sharma, Jay M. Lee
  • Interleukin 15 fusion protein for tumor targeting therapy
    Patent number: 11236140
    Abstract: Disclosed is a tumor-targeting fusion protein comprising at least (i) a IL-15 peptide or a variant or functional fragment thereof, (ii) a IL-15R? polypeptide or a variant or functional fragment thereof, (iii) a Fc domain or a variant or functional fragment thereof, and (iv) a RGD polypeptide or a variant thereof. The fusion protein is preferably configured as RGD polypeptide-Fc domain-IL-15 polypeptide-IL-15R? polypeptide. The tumor-targeting fusion proteins provided herein improves the anti-tumor effects of IL-15 and prolongs the half-life of IL-15, while targeting tumor sites and acting upon tumor cells. In addition, the fusion proteins are capable of being expressed at high efficiency and purified. The high efficiency of anti-tumor activity enables the fusion proteins to be an excellent candidate for tumor immunotherapy.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: February 1, 2022
    Assignee: BJ Bioscience Inc.
    Inventors: Zhong Wang, Qing Li
  • Targeted mutant interferon-beta and uses thereof
    Patent number: 11236141
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: February 1, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman
  • Acylated oxyntomodulin peptide analog
    Patent number: 11236142
    Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Assignee: DONG-A ST CO., LTD.
    Inventors: Jae-Sung Yang, Kyung-Seok Lee, Yu-Na Chae, Gye-Rim Baek, Tae-Hyoung Kim, Ill-Hun Jung, Chae-Lim Ryu, Weon-Bin Im
  • Extracellular vesicle comprising a fusion protein having Fc binding capacity
    Patent number: 11236143
    Abstract: The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs are coated with proteins containing Fc domains (such as antibodies) for i.a. targeting and therapeutic applications. The coating of EVs is achieved through inventive protein engineering of EV polypeptides. The present invention thus relates to methods for coating of EVs, EVs per se, as well as pharmaceutical compositions and medical applications of such EVs coated with Fc containing proteins.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 1, 2022
    Assignee: Evox Therapeutics Ltd
    Inventors: Oscar Wiklander, André Görgens, Dhanu Gupta
  • Antibodies against novel PD1 isoforms and uses thereof
    Patent number: 11236144
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 1, 2022
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • T cell receptors and immune therapy using the same against PRAME positive cancers
    Patent number: 11236145
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 1, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • Stable pharmaceutical formulation
    Patent number: 11236146
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 1, 2022
    Assignee: Celltrion Inc.
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Kwang Woo Kim, Yeon Kyeong Shin
  • Methods and compositions for the inhibition of TRPV4
    Patent number: 11236147
    Abstract: TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 1, 2022
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Mariko Kobayashi
  • Method for the design of fibrillar collagen-mimetic peptide self-assemblies
    Patent number: 11236148
    Abstract: Novel synthetic human scale collagen triple helices assemblies are disclosed. Methods of making self-assembling collagen mimetic peptides that self-assemble into human scale collagen are also disclosed.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: February 1, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Ronald T. Raines, Ismet Tanrikulu